Indicated for the treatment of the signs and symptoms of allergic conjunctivitis.
H1-Receptor Antagonist; Antiallergy
Olopatadine, an antihistamine, works by blocking the action of histamine in the body, which reduces allergy symptoms. Olopatadine hydrochloride treats sneezing, itching, runny nose, and other nasal symptoms of allergies.
Mode of Action: Olopatadine is an anti-allergic molecule that works via several mechanisms. As a mast cell stabilizer, it stabilizes rodent basophils and human conjunctival mast cells and inhibits the immunologically-stimulated release of histamine. Olopatadine acts as an antagonist at the histamine H1 receptors with high selectivity, Upon binding, olopatadine blocks the H1 receptor signaling pathway, inhibiting the release of inflammatory mediators, such as tryptase, prostaglandin D2, TNF-alpha, as well as pro-inflammatory cytokines.
Pharmacokinetics: Absorption: Olopatadine was absorbed with individual peak plasma concentrations observed between 30 minutes and 1 hour after twice daily intranasal administration of Olopatadine Nasal Spray. Distribution: The protein binding of olopatadine was moderate at approximately 55% in human serum, and independent of drug concentration over the range of 0.1 to 1000 ng/mL. Metabolism: Olopatadine is not extensively metabolized. Based on plasma metabolite profiles of olopatadine, at least six minor metabolites circulate in human plasma. Elimination: The plasma elimination half-life of olopatadine is 8 to 12 hours. Olopatadine is mainly eliminated through urinary excretion
For the treatment of the signs and symptoms of allergic conjunctivitis, including ocular pruritus. Ophthalmic dosage (Patanol 0.1%) Adults, Adolescents, and Children 3 years and older 1 drop in each affected eye twice daily at an interval of 6 to 8 hours. Ophthalmic dosage (Pataday 0.2% and Pazeo 0.7%) Adults, Adolescents, and Children 2 years and older 1 drop in each affected eye once a day. For the treatment of symptoms associated with seasonal allergic rhinitis such as rhinorrhea, sneezing, and nasal pruritus. Intranasal dosage Adults, Geriatric, Adolescents, and Children >= 12 years 2 sprays (665 mcg/spray) in each nostril twice daily. Children 6—11 years 1 spray (665 mcg/spray) in each nostril twice daily. Children 2—5 years† 1 spray (665 mcg/spray) in each nostril twice daily has been evaluated in 66 children aged 2—5 years for safety; however, efficacy has not been established in this population.
Formal drug-drug interaction studies were not conducted for Olopatadine Nasal Spray. Drug interactions with inhibitors of liver enzymes are not anticipated because olopatadine is eliminated predominantly by renal excretion. Drug interactions involving P450 inhibition and plasma protein binding are also not expected.
Hypersensitivity. Ophthalmic: Children <3 yr. Nasal: Children <12 yr. Pregnancy, lactation. Ophthalmic: Remove contact lenses prior to eye admin. Reinsert soft contact lenses 10 min after admin.
Ophthalmic: Headache; asthenia; cold syndrome; pharyngitis; rhinitis; sinusitis: dysgeusia; ocular burning or stinging; dry eye; foreign body sensation; hyperaemia; keratitis; lid oedema; ocular pruritus; blurred vision. Nasal: Bitter taste, nasal ulceration, epistaxis, drowsiness.
Animal studies have shown reproductive toxicity. There are no adequate and well-controlled studies in pregnant women. Use is not recommended. Use is not recommended during breastfeeding.
There is no information on Olopatadine overdose. However, excessive use of any medication can have serious consequences. If you suspect an overdose, seek medical attention without delay.
Store at room temperature and protect from light. It is desirable that the contents should not be used more than one month after first opening of the bottle.
.png&w=384&q=75)